WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program.
The court declined to take up lawsuits against the program by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The justices did not provide a reason for their decision, which was anticipated given the drugmakers’ previous losses in lower courts. Typically, the Supreme Court refrains from hearing cases where there is consensus among lower courts.
This ruling underscores the increasing challenges faced by pharmaceutical companies in navigating regulatory frameworks that seek to control drug pricing. As the Medicare program moves forward with negotiations, stakeholders in the pharmaceutical sector, particularly in regulatory and compliance roles, must prepare for a landscape where price negotiations are not only commonplace but also legally upheld.
Use the database as your supply chain compass →
